These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 2673693

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
    Johnson AB, Taylor R.
    Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
    [Abstract] [Full Text] [Related]

  • 3. alpha-Glucosidase inhibition by miglitol in NIDDM patients.
    Kingma PJ, Menheere PP, Sels JP, Nieuwenhuijzen Kruseman AC.
    Diabetes Care; 1992 Apr; 15(4):478-83. PubMed ID: 1499461
    [Abstract] [Full Text] [Related]

  • 4. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
    Drent ML, Tollefsen AT, van Heusden FH, Hoenderdos EB, Jonker JJ, van der Veen EA.
    Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
    [Abstract] [Full Text] [Related]

  • 5. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
    Johnston PS, Feig PU, Coniff RF, Krol A, Davidson JA, Haffner SM.
    Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
    [Abstract] [Full Text] [Related]

  • 6. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
    Mitrakou A, Tountas N, Raptis AE, Bauer RJ, Schulz H, Raptis SA.
    Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
    [Abstract] [Full Text] [Related]

  • 7. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
    Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL.
    J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
    Heinz G, Komjati M, Korn A, Waldhäusl W.
    Eur J Clin Pharmacol; 1989 May; 37(1):33-6. PubMed ID: 2687007
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Miglitol (BAY m 1099) treatment of diabetic hypothalamic-dietary obese rats improves islet response to glucose.
    Axen KV, Li X, Sclafani A.
    Obes Res; 1999 Jan; 7(1):83-9. PubMed ID: 10023734
    [Abstract] [Full Text] [Related]

  • 14. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.
    Sels JP, Nauta JJ, Menheere PP, Wolffenbuttel BH, Nieuwenhuijzen Kruseman AC.
    Br J Clin Pharmacol; 1996 Oct; 42(4):503-6. PubMed ID: 8904624
    [Abstract] [Full Text] [Related]

  • 15. Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
    Scott AR, Tattersall RB.
    Diabet Med; 1988 Jan; 5(1):42-6. PubMed ID: 2964327
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Miglitol, a new alpha-glucosidase inhibitor.
    Sels JP, Huijberts MS, Wolffenbuttel BH.
    Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.